Activist investor Elliott pushed for targets at PepsiCo, and Reuters reports the clock is ticking while GLP-1 drugs weigh on snack demand.
Recap by typeshit. Full story at Reuters.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Joshi explains how medicines first built for diabetes grew into newer GLP-1 therapies used for substantial weight reduction.
A short post urging careful screening and ongoing support before GLP-1 drugs are used by anyone with past eating disorders.
Loading…